Neuspera Medical Raises $23 Million in Series D Financing led by Vertex Ventures HC and Treo Ventures

Neuspera Medical, Inc., a neuromodulation company, has closed its Series D funding round, raising $23 million. The round was led by Vertex Ventures HC and Treo Ventures, with participation from Action Potential Venture Capital, Windham Venture Partners, Olympus Innovation Ventures, and another strategic investor. The funding will support the expected U.S. Food and Drug Administration (FDA) premarket approval (PMA) of the Neuspera System, designed to provide relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB).